Document is current
Any future updates will be listed below
-
Authors
Naveed, Ahmed https://orcid.org/0009-0002-8884-9967
Recinos, Elissa
Chow, Dexter
Degan, Chiara
Tsonaka, Roula
Guglieri, Michela
Al-Khalili Szigyarto, Cristina
Spitali, Pietro
van der Burgt, Yuri E. M.
Diaz-Manera, Jordi
Dang, Utkarsh J.
,
Hathout, Yetrib
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R61NS119639)
- License Information
-
More Information
Article History
Received: 25 February 2026
Accepted: 12 May 2026
First Online: 6 June 2026
Declarations
:
: The FOR-DMD study was registered at ClinicalTrials.gov (registration no. NCT01603407). Serum samples and clinical data were collected following approval from the competent ethics committee at each institution in accordance with the International Conference on Harmonisation guidelines for Good Clinical Practice and the World Medical Association Declaration of Helsinki. Central Institutional Review Board (IRB) approval for the original FOR-DMD study was obtained from the University of Rochester Ethics Committee/IRB and the Newcastle Clinical Trial Unit (NCTU) before the distribution of study documents to each investigative site and the enrollment of participants. Informed written consent for participation in biomarker research was obtained from the parents or legal guardians of participants at the time of enrollment in the clinical study.
: The authors declare no competing interests.
